AbbVie Sues HHS over Botox Pick for Medicare Drug Price Negotiation
- February 13, 2026
AbbVie, Inc. is suing the Department of Health and Human Services (HHS) over the agency’s decision to select the company’s Botox® product for the Medicare drug price negotiation program.
ARTICLE TAGS
You must be logged in to access this content.